Digital RESI Pitch Session
Interested in Connecting? Please contact:
Jacqueline Iversen, RPh, MS
Founder & Head of Clinical Development
jiversen@sen-jam.com
Message the company or request a 1:1 meeting here.
Sen-Jam Pharmaceutical’s innovation begins with repurposing small molecules to advance therapeutics for the greater good of society with a worldwide reach. We have 24 patents awarded and pending while we develop the safest, oral, and most potent anti-inflammatory with non-opioid pain relief.
When COVID-19 became the world’s challenge, Sen-Jam did, what Sen-Jam does. We re-tooled our product to address SARS-CoV-2. Our product (SJP-002) provides anti-viral plus potent broad spectrum anti-inflammatory capabilities to modulate the disease course of COVID-19. SJP-002 was specifically designed to be oral, safe, inexpensive, potent, yet accessible to all. In 12 weeks we have established partnerships around the world and we plan to be in human trials Summer 2020!